JP2022536913A5 - - Google Patents

Info

Publication number
JP2022536913A5
JP2022536913A5 JP2021573799A JP2021573799A JP2022536913A5 JP 2022536913 A5 JP2022536913 A5 JP 2022536913A5 JP 2021573799 A JP2021573799 A JP 2021573799A JP 2021573799 A JP2021573799 A JP 2021573799A JP 2022536913 A5 JP2022536913 A5 JP 2022536913A5
Authority
JP
Japan
Application number
JP2021573799A
Other languages
Japanese (ja)
Other versions
JP2022536913A (ja
JPWO2020252478A5 (https=
JP7680968B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/037791 external-priority patent/WO2020252478A2/en
Publication of JP2022536913A publication Critical patent/JP2022536913A/ja
Publication of JP2022536913A5 publication Critical patent/JP2022536913A5/ja
Publication of JPWO2020252478A5 publication Critical patent/JPWO2020252478A5/ja
Priority to JP2025078387A priority Critical patent/JP2025121997A/ja
Application granted granted Critical
Publication of JP7680968B2 publication Critical patent/JP7680968B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021573799A 2019-06-14 2020-06-15 Ｐｄ－１に対する抗体およびその使用方法 Active JP7680968B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025078387A JP2025121997A (ja) 2019-06-14 2025-05-09 Ｐｄ－１に対する抗体およびその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962861638P 2019-06-14 2019-06-14
US62/861,638 2019-06-14
US201962884473P 2019-08-08 2019-08-08
US62/884,473 2019-08-08
PCT/US2020/037791 WO2020252478A2 (en) 2019-06-14 2020-06-15 Antibodies against pd-1 and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025078387A Division JP2025121997A (ja) 2019-06-14 2025-05-09 Ｐｄ－１に対する抗体およびその使用方法

Publications (4)

Publication Number Publication Date
JP2022536913A JP2022536913A (ja) 2022-08-22
JP2022536913A5 true JP2022536913A5 (https=) 2023-06-20
JPWO2020252478A5 JPWO2020252478A5 (https=) 2023-06-20
JP7680968B2 JP7680968B2 (ja) 2025-05-21

Family

ID=73782142

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021573799A Active JP7680968B2 (ja) 2019-06-14 2020-06-15 Ｐｄ－１に対する抗体およびその使用方法
JP2025078387A Pending JP2025121997A (ja) 2019-06-14 2025-05-09 Ｐｄ－１に対する抗体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025078387A Pending JP2025121997A (ja) 2019-06-14 2025-05-09 Ｐｄ－１に対する抗体およびその使用方法

Country Status (6)

Country Link
US (1) US20220249640A1 (https=)
EP (1) EP3983444A4 (https=)
JP (2) JP7680968B2 (https=)
AU (1) AU2020291946A1 (https=)
CA (1) CA3141927A1 (https=)
WO (1) WO2020252478A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7769007B2 (ja) * 2020-12-23 2025-11-12 イミュノウェイク インコーポレイテッド イムノサイトカイン及びその使用
IL305758A (en) * 2021-03-10 2023-11-01 Immunowake Inc Immunomodulatory compounds and their uses
WO2023076177A2 (en) * 2021-10-25 2023-05-04 Genvivo, Inc. Compositions and methods for therapeutic delivery

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1753912B (zh) * 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
AU2005203962C1 (en) * 2004-01-05 2012-11-08 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
ES2398076T3 (es) * 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
US20100233154A1 (en) * 2008-10-08 2010-09-16 Medimmune Limited Targeted binding agents directed to heparanase and uses thereof 463
CA3101783C (en) * 2011-10-11 2023-01-31 Universitat Zurich Prorektorat Mnw Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
CN108250303B (zh) 2016-12-19 2023-01-03 南京金斯瑞生物科技有限公司 单域抗体融合蛋白及其应用
KR102746901B1 (ko) * 2017-03-03 2024-12-26 옵시디안 테라퓨틱스, 인크. Cd19 조성물 및 면역요법을 위한 방법
US20230192839A1 (en) * 2017-04-12 2023-06-22 Pfizer Inc. Antibodies having conditional affinity and methods of use thereof
CN109422815A (zh) * 2017-08-28 2019-03-05 复旦大学 双特异性嵌合抗原受体c-Met/PD-1 scFv-CAR-T及其构建方法和应用
WO2020113224A2 (en) * 2018-11-30 2020-06-04 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptor factories and methods of use thereof

Similar Documents

Publication Publication Date Title
CL2025003792A1 (es) Proceso para sintetizar derivados de naftiridina y sus compuestos intermedios.
JP2022536913A5 (https=)
BR112021013417A2 (https=)
CN305800736S (https=)
CN305798357S (https=)
CN305535153S (https=)
CN305532770S (https=)
CN305532333S (https=)
CN305531142S (https=)
CN305801969S (https=)
CN305530642S (https=)
CN305858352S (https=)
CN305874930S (https=)
CN305530509S (https=)
CN305798652S (https=)
CN305793420S (https=)
CN305797987S (https=)
CN305797022S (https=)
CN305795658S (https=)
CN305795000S (https=)
CN305794720S (https=)
CN305529868S (https=)
CN305529862S (https=)
CN305535806S (https=)
CN305793488S (https=)